NSG/501 Week 1: Population, Disease Process and Risk Factors, sample paper

The First Break Is a Warning: Osteoporosis in Women Over 65 After a Wrist Fracture, From Bone Remodeling to Risk Factors

[Student Name]

University of Phoenix

NSG/501: Pathophysiology, Assessment Variables and Pharmacology I

Week 1 Assignment

[Instructor Name]

[Date]

The clinic and its population are a composite written for a model paper.

In the orthopedic clinic where I work, a woman in her late sixties with a cast on her wrist is one of the most common patients of the week. She slipped on ice or tripped over a rug, put out her hand and heard the bone break. The fracture heals in six weeks, the cast comes off and she is discharged. Very often, no one asks why a fall from standing height broke her wrist. This paper selects that population, women aged 65 and older seen after a first fragility fracture of the distal radius, and explains the disease that most often lies behind the fracture: postmenopausal osteoporosis. The wrist fracture is not the disease; it is the first visible sign of a disease that has been developing silently for years.

The Population

The population for this course is women 65 years of age and older seen in an outpatient orthopedic clinic within three months of a low-trauma distal radius fracture. The population is narrow on purpose. Women in this age group have the highest rates of osteoporosis, the wrist fracture gives a clear moment when they are in contact with the health system, and they are at high risk of a second, more serious fracture. In our clinic, they are also rarely referred for bone density testing or treatment, a gap that later weeks will address.

What Osteoporosis Is

Osteoporosis is a skeletal disease in which low bone mass and deterioration of bone microarchitecture make bone fragile and prone to fracture (Compston et al., 2019). It is diagnosed by bone density testing, with a T-score of minus 2.5 or lower at the hip or spine, or clinically, in the presence of a fragility fracture of the hip or spine. The disease produces no symptoms until a bone breaks, which is why it is so often found late.

The Bone Remodeling Cycle

The skeleton is never finished: throughout adult life, small packets of bone are removed and replaced at thousands of sites at once. Osteoclasts, large cells derived from the monocyte line, resorb old or damaged bone, creating small cavities. Osteoblasts, derived from mesenchymal stem cells, then lay down new bone matrix, which mineralizes over the following months. In young adults, resorption and formation are balanced, so bone mass remains stable.

The balance is regulated by signaling between the cells. Osteoblasts and osteocytes produce a protein called receptor activator of nuclear factor kappa-B ligand, known as RANKL, which binds to its receptor on osteoclast precursors and drives them to mature and resorb bone. Osteoblasts also produce osteoprotegerin, a decoy receptor that binds RANKL and blocks it. The ratio of RANKL to osteoprotegerin sets how active osteoclasts will be (Compston et al., 2019). This pathway matters later in the course, because one of the main drugs for osteoporosis works by blocking RANKL.

What Changes After Menopause

Estrogen restrains osteoclasts, in part by lowering RANKL expression and raising osteoprotegerin. When estrogen falls at menopause, osteoclast formation and activity rise, more remodeling units open at the same time and each resorbs more bone than osteoblasts can replace. Bone is lost fastest in the first five to ten years after menopause, with trabecular bone, the lattice-like bone of the vertebrae and the distal radius, affected first because it has more surface for remodeling. Trabeculae thin, lose their connections and perforate, and the bone loses strength faster than density alone would suggest.

With age, a second process adds to the first. Osteoblast function declines, calcium absorption from the gut falls and vitamin D production in the skin decreases, so the body raises parathyroid hormone to maintain blood calcium, which increases resorption further. Cortical bone, the dense outer shell of the long bones, becomes thinner and more porous. The result is a skeleton that can break in a fall that would once have caused only a bruise.

Risk Factors, Linked to the Mechanism

Risk factors for osteoporotic fracture fall into two groups. Those that cannot be changed include female sex, older age, White or Asian ancestry, a parent with a hip fracture, early menopause and, most importantly for this population, a prior fragility fracture. Each works through the mechanism above: lower peak bone mass, longer exposure to estrogen deficiency or more years of age-related decline.

Those that can be changed include low body weight, smoking, drinking three or more alcoholic drinks a day, low calcium and vitamin D intake, physical inactivity, long-term glucocorticoid use and medical conditions such as rheumatoid arthritis. Glucocorticoids, for example, suppress osteoblasts and increase osteoclast survival, shifting the remodeling balance toward loss. Fracture risk calculators such as FRAX combine many of these factors with age and, when available, bone density to estimate a person's ten-year probability of a hip fracture and of a major osteoporotic fracture (Kanis et al., 2008).

Why Men and Younger Women Are Left Out

Narrowing the population means leaving people out, and the choice should be explained. Men also develop osteoporosis and suffer fragility fractures, usually about a decade later than women, and their fractures carry a higher mortality. Younger postmenopausal women with wrist fractures are also at risk. This course focuses on women over 65 because they form the largest group in the clinic, because the mechanism of estrogen-driven bone loss is shared across the group and because age-based screening recommendations already apply to them, so the gap between what should happen and what does happen is clearest. A later project could extend the same approach to men and to younger women, with the education adapted to their different reasons for bone loss, such as low testosterone, alcohol or glucocorticoid use.

Why This Population Needs Attention

A wrist fracture in this population is a warning with a short window. A prior fragility fracture is one of the strongest predictors of a future one, and the next fracture is more likely to be a vertebra or a hip, which carries far greater disability and mortality. Yet treatment after a fracture is uncommon. In a national study of 96,887 insured patients hospitalized for hip fracture between 2002 and 2011, the estimated probability of receiving osteoporosis medication within a year of discharge was only 28.5%, and it fell over the decade from 40.2% to 20.5% (Solomon et al., 2014). If treatment is this rare after a hip fracture, it is likely rarer after a wrist fracture seen only in a clinic.

Plan for the Coming Weeks

The rest of this course will follow the same population. Week 2 will interpret assessment findings for a typical patient from the clinic and identify education priorities. Week 3 will map the disease in a concept map. Weeks 4 and 5 will evaluate the drug treatment and the full plan of care, and Week 6 will design an education intervention to close the treatment gap after a first fracture.

Conclusion

Postmenopausal osteoporosis develops when estrogen loss and aging shift bone remodeling toward resorption, thinning trabecular and cortical bone until a minor fall breaks it. Women over 65 seen after a first wrist fracture are the right population for this course because the fracture reveals the disease, predicts the next fracture and opens a window for treatment that is usually missed.

References

Compston, J. E., McClung, M. R., & Leslie, W. D. (2019). Osteoporosis. The Lancet, 393(10169), 364-376. https://doi.org/10.1016/S0140-6736(18)32112-3

Kanis, J. A., Johnell, O., Oden, A., Johansson, H., & McCloskey, E. (2008). FRAX and the assessment of fracture probability in men and women from the UK. Osteoporosis International, 19(4), 385-397. https://doi.org/10.1007/s00198-007-0543-5

Solomon, D. H., Johnston, S. S., Boytsov, N. N., McMorrow, D., Lane, J. M., & Krohn, K. D. (2014). Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. Journal of Bone and Mineral Research, 29(9), 1929-1937. https://doi.org/10.1002/jbmr.2202